Potential benefit of bosentan therapy in borderline or less severe pulmonary hypertension secondary to idiopathic pulmonary fibrosis—an interim analysis of results from a prospective, single-center, randomized, parallel-group study https://t.co/r38XpnihZ
IPF pts with PH may benefit from bosentan therapy to improve IPF and prognosis? https://t.co/L60Lg3RK8t
Potential benefit of #bosentan in pulmonary hypertension secondary to #IPF #RespEd Time to exacerbation of subjective dyspnea, to an increase in the dose of O2, hospital-free survival, overall survival. https://t.co/W8hJqAcpja https://t.co/LnpYn3RbmH
Potential benefit of bosentan therapy in borderline or less severe pulmonary hypertension secondary to idiopathic pulmonary fibrosis-an interim analysis of results from a prospective, single-center, randomized, parallel-group study. https://t.co/VcK2n9HOpe